Log in
Enquire now
‌

US Patent 8088781 Inhibitors of brutons tyrosine kinase

Patent 8088781 was granted and assigned to Pharmacyclics on January, 2012 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
Pharmacyclics
Pharmacyclics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
80887810
Patent Inventor Names
Tarak D. Mody0
Erik Verner0
Lee Honigberg0
Zhengying Pan0
Date of Patent
January 3, 2012
0
Patent Application Number
123564980
Date Filed
January 20, 2009
0
Patent Citations Received
‌
US Patent 11884740 Anti-CD20 antibody compositions
0
‌
US Patent 11965032 Anti-CD20 antibody compositions
0
‌
US Patent 11672803 Use of inhibitors of Brutons tyrosine kinase (Btk)
0
Patent Primary Examiner
‌
Jeffrey Murray
0
Patent abstract

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8088781 Inhibitors of brutons tyrosine kinase

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.